Fourth-quarter net income extended 14% to $40.5 million, or $3.07 per share. Deckers' earnings included a non-cash writedown of $20.9 million because of goodwill impairment applicable to its Teva moreover TSUBO brands. (Writedowns relevant to the Teva brand are nothing new, although; this was going forth latest quarter, to boot.)
Revenue increased 56.3% to $303.5 million, despite UGG sales being the bright spot, up 62% in the quarter. Teva's brand continues to struggle, however.
It seems what really spooked investors was Deckers' forecast for the future.